TG THERAPEUTICS, INC. Costs and Expenses
TG THERAPEUTICS, INC. (TGTX) reported Costs and Expenses of $218.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-05
- TG THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-06-30 was $218.66M, a 105.69% increase year-over-year.
- TG THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-03-31 was $170.12M, a 51.58% increase year-over-year.
- TG THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-12-31 was $142.08M, a 81.60% increase year-over-year.
- TG THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-09-30 was $132.34M, a 85.24% increase year-over-year.
- TG THERAPEUTICS, INC. costs and expenses for fiscal 2025 was $492.96M, a 71.72% increase from fiscal 2024.
- TG THERAPEUTICS, INC. costs and expenses for fiscal 2024 was $287.07M, a 34.76% increase from fiscal 2023.
- TG THERAPEUTICS, INC. costs and expenses for fiscal 2023 was $213.03M, a 3.65% decline from fiscal 2022.
- TG THERAPEUTICS, INC. costs and expenses for fiscal 2022 was $221.10M, a 37.09% decline from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $218.66M 10-Q · filed 2026-08-05 | $388.78M 10-Q · filed 2026-08-05 | $530.86M derived: sum of 3 quarters · filed 2026-08-05 | $663.21M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $170.12M 10-Q · filed 2026-05-06 | $312.20M derived: sum of 2 quarters · filed 2026-05-06 | $444.55M derived: sum of 3 quarters · filed 2026-05-06 | $550.85M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $142.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $274.42M derived: sum of 2 quarters · filed 2026-02-27 | $380.73M derived: sum of 3 quarters · filed 2026-08-05 | $492.96M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $132.34M 10-Q · filed 2025-11-05 | $238.65M derived: sum of 2 quarters · filed 2026-08-05 | $350.88M 10-Q · filed 2025-11-05 | $429.12M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $106.31M 10-Q · filed 2026-08-05 | $218.54M 10-Q · filed 2026-08-05 | $296.77M derived: sum of 3 quarters · filed 2026-08-05 | $368.22M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $112.23M 10-Q · filed 2026-05-06 | $190.47M derived: sum of 2 quarters · filed 2026-05-06 | $261.92M derived: sum of 3 quarters · filed 2026-05-06 | $326.56M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $78.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $149.68M derived: sum of 2 quarters · filed 2026-02-27 | $214.33M derived: sum of 3 quarters · filed 2026-02-27 | $287.07M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $71.44M 10-Q · filed 2025-11-05 | $136.09M derived: sum of 2 quarters · filed 2025-11-05 | $208.84M 10-Q · filed 2025-11-05 | $265.30M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $64.65M 10-Q · filed 2025-08-08 | $137.39M 10-Q · filed 2025-08-08 | $193.85M derived: sum of 3 quarters · filed 2026-02-27 | $244.88M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | $72.74M 10-Q · filed 2025-05-09 | $129.20M derived: sum of 2 quarters · filed 2026-02-27 | $180.23M derived: sum of 3 quarters · filed 2026-02-27 | $240.98M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | $56.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $107.49M derived: sum of 2 quarters · filed 2026-02-27 | $168.24M derived: sum of 3 quarters · filed 2026-02-27 | $213.03M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $51.03M 10-Q · filed 2024-11-07 | $111.78M derived: sum of 2 quarters · filed 2024-11-07 | $156.57M 10-Q · filed 2024-11-07 | $234.19M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $60.75M 10-Q · filed 2024-08-09 | $105.54M 10-Q · filed 2024-08-09 | $183.16M derived: sum of 3 quarters · filed 2025-03-03 | $218.22M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $44.80M 10-Q · filed 2024-05-06 | $122.41M derived: sum of 2 quarters · filed 2025-03-03 | $157.47M derived: sum of 3 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $77.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $112.68M derived: sum of 2 quarters · filed 2025-03-03 | $221.10M 10-K · filed 2025-03-03 | $195.62M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $35.06M 10-Q · filed 2023-11-06 | $143.48M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $351.46M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |